Author: fosemckay

Typically, pharmacy benefit managers (PBMs) reduce drug-benefit costs up to 30 percent for more than 266 million Americans enrolled in private and public plans, most notably Medicare Part D. The PBM industry emerged in response to a wave of expensive new blockbuster drugs that began...

Recently, three changes in the health care terrain collided to raise new concerns over rising drug prices: the advent of new high-priced “wonder drugs” like Sovaldi...

A research team from Harvard, Northwestern and the University of California, Los Angeles, looked at brand-name drugs that also had generic equivalents. When drug companies offered a coupon for the brand-name version, more patients stuck with the more expensive brand-name drug, and the company raised...

It’s not surprising that EpiPen maker Mylan would defend its 400% price increase with the line that it’s okay because it’s generally covered by insurance. That’s the pharmaceutical industry way–for years now–to say that patients aren’t getting hurt when drug prices rise....

Outrage over escalating prices for Mylan’s EpiPen forced the company to react Thursday, as lawmakers demanded relief for parents with children susceptible to severe allergic reactions to food or to bee stings who found themselves forced to add the $608 drug device to their lists...